MEGGLE family fights back against leukemia
Press Release | MEGGLE Excipients & Technology
MAY 11, 2018
Wasserburg, Germany: – The entire dairy workforce at German-based pharmaceutical lactose specialist MEGGLE Excipients & Technology (MEGGLE), has banded together to stage an anti-leukemia initiative after one of their number fell victim to the cancer of the blood cells.
When a dairy production worker received a leukemia diagnosis, colleagues banded together to organize a stem cell typification campaign to identify a potential bone marrow donor.
Special typing is necessary to find a genetic twin, whose stem cells could match the patient’s DNA profile. Volunteers give DNA swabs that then can be analyzed in a laboratory. This is the first step to become a potential life saver.
The campaign was led by MEGGLE company physician, Dr. Gertrud Huber, with support from Germany’s bone marrow donor organization, the DKMS.
More than 165 MEGGLE workers participated in the typification campaign. Apprentices, members of Human Resources and the work council joined forces to ensure a fast procedure.
The campaign was publicized via internal notice boards, posters around the factory site and group mailings.
Spreading the message
“Direct talks at the canteen and car park during the shift change encouraged more people to participate in the typification,” said MEGGLE Human Resources Director, Doris Kollmannsberger.
“We hope that we are now able to help our colleague and maybe other patients with this disease. At the very least, we have alerted our people to the risks of leukemia and blood cancer, ‘ said Ms. Kollmannsberger.
“A few of our employees were already registered as potential donors and so didn’t need to be typified again,” she explained.
About MEGGLE Wasserburg
Bavarian-based MEGGLE Wasserburg is one of the world’s experts in lactose based excipients and powder technology.
From its roots as a dairy operation in the late 1880s, MEGGLE has become one of the world’s leading manufacturers of pharmaceutical lactose, supplying the pharma market segment with a broad-based and unique lactose product portfolio.
MEGGLE Excipients & Technology has harnessed outstanding product quality and intelligent innovation to become a global leader in the manufacture of lactose-based excipients, focusing on products for direct tableting and dry powder inhalation.
A multidisciplinary team of committed and highly qualified people allows MEGGLE clients to benefit from pioneering experience and innovative drive in industrial milk and whey processing. The company constantly strives to develop high-tech, functional products for solid dosage form applications, where they can deliver maximum performance.
The company has introduced several pioneering products, notably Tablettose®, the world’s first agglomerated lactose for direct tableting, Cellactose® 80, a pioneering co-processed excipient based on cellulose-lactose for outstanding compression and flow properties and RetaLac®, the first direct compression co-processed excipient using a hypromellose-lactose base for modified sustained release and controlled release formulations.
Margit Bonnetsmüller, Project Manager Marketing, MEGGLE Excipients & Technology Business Group
Tel: +49 8071 73 476